PATENT CLAIM ANALYSIS

Application Number: 16173071
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "381000"]

Abstract:
A leukotriene C4 and D4 antagonist is used to inhibit tumor metastasis by acting to inhibit tumor cell adhesion to endothelial cells, thereby preventing tumor cell extravasation.

Claim (Index 4):
The method according to  claim 1 , wherein the leukotriene C4 and D4 receptor antagonist is administered orally.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 97.0
- Lexical Diversity: 1.26087
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['10721742', '10559260', '13209866', '15270669', '15301438']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7769491528574144
- 35 USC 102 Novelty (BERT): 0.523376524108077
- Combined Prediction Score: 0.7515918899824806
- Mean Citation Score: 240.17449
- Max Citation Score: 300.8493
- Similarity Product: 182.0688117982507

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test